Tuesday, December 7, 2021

Covaxin

Bharat Biotech’s Ankleshwar unit gets nod to make Covaxin

Bharat Biotech recently stated that products manufactured from Ankleshwar will be available for supplies during September.

Hyderabad: Special offer for Covaxin in Apollo Hospitals from Aug 12-21

Under the special freedom offer, Apollo Hospitals will offer the Covaxin vaccine at a no profit cost price of Rs.1,250.

Mixing Covishield, Covaxin provides better immunity: ICMR

The results of a study conducted by ICMR showed that the people in the mix and match group had superior immunogenicity profiles against Alpha, Beta and Delta variants of Covid-19

Covaxin under review process in Canada: Bharat Biotech’s partner Ocugen

Ocugen said Bharat Biotech completed and posted its phase 3 clinical trial results for Covaxin demonstrating 77.8 per cent efficacy against overall Covid-19 disease

Bharat Biotech allays fears over quality of Covaxin

Says supply of nearly 70 million doses of its Covid-19 vaccine to date proves its safety standards

Covaxin receives Good Manufacturing Practice certificate from Hungary

The approval has been received from the National Institute of Pharmacy and Nutrition, Hungary, certifying the GMP for the manufacture of Covaxin.

Editorial: Double the vaccination rate

More than half of the adult population has yet to receive even a single dose, despite a slight improvement in coverage in July

Committed to supply 50 crore vaccine doses to Centre: Bharat Biotech

The company had supplied about four billion doses to about 125 countries and will continue to ramp up production at its four plants in the country, said Suchitra Ella, co-founder of Bharat Biotech

Vaccines reduce ‘Delta’ severity: Study

The rate of mortality was found to be about 50% lower in fully vaccinated individuals having a breakthrough infection, according to CCMB, AIg study

Only 0.4% mortality among vaccinated: ICMR

The analysis of breakthrough cases is a clear indication that vaccines are the best bet to reduce severity and fatalities among Covid-19 patients.

Decision on emergency use listing of Covaxin likely in 4-6 weeks: WHO

Speaking at a webinar organised by the Centre for Science and Environment (CSE) on Friday, Swaminathan said the WHO is reviewing Covaxin as its manufacturer Bharat Biotech is now uploading its entire data

All you need to know about Kappa variant of Covid-19

Hyderabad: After the Delta and Delta Plus variants of the Covid-19, a new strain – Kappa – has been discovered and three people infected...

Covid vaccine availability to improve across country in coming months

Drug regulatory authorities keen on fast-tracking approvals of new Covid vaccine candidates

Phase 3 trial data shows Covaxin to be 77.8% effective against Covid-19

Efficacy data also demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant, the company said in a statement while announcing its phase 3 data analysis.

Centre allocates 28 lakh vaccine doses to Telangana for July

The Union Health Ministry on Thursday projected that it will be able to supply 27,99,290 doses to Telangana in July.

Latest News

- Advertisement -